The Kellett and Brown groups recently published a collaborative article "Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination" in the Oxford journal, Nucleic Acid Research. The work showed how di-nuclear metal complexes with artificial nuclease activity promote cancer cell death and selectively bind DNA sequences with TA/TA or AT/AT steps. The compounds were active against solid epithelial cancer cells from the National Cancer Institute’s 60 human cell line panel (NCI-60) indicating exciting future therapeutic applications for this class of molecule.